EUVIMEDEUVIMED entdecken
Open Access

Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS G12C -Mutated Non–Small Cell Lung Cancer: A Case Series and Literature Review

Jia Luo iD, Narjust Florez iD, Anjali Donnelly, Yanyan Lou iD, Kevin Lu iD, Patrick C Ma, Alexander I Spira iD, Debra Ryan, Hatim Husain iD

JCO Precision Oncology · 2024-12 · (8)

DOI: 10.1200/po.23.00644 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024-12. Verfasst von Jia Luo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Acetonitriles, Carcinoma, Non-Small-Cell Lung, Chemical and Drug Induced Liver Injury, Lung Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE KRAS is the most commonly mutated driver oncogene in non–small cell lung cancer (NSCLC). Sotorasib and adagrasib, KRAS G12C inhibitors, have been granted accelerated US approval; however, hepatotoxicity is a common side effect with higher rates in patients treated with sotorasib proximal to checkpoint inhibitor (CPI) therapy. The aim of this study was to assess the feasibility and safety of adagrasib after discontinuation of sotorasib because of treatment-related grade 3 hepatotoxicity through real-world and clinical cases. METHODS Medical records from five patients treated in real-world settings were retrospectively reviewed. Patients had locally advanced or metastatic KRAS G12C -mutated NSCLC and received adagrasib after sotorasib in the absence of extracranial disease progression. Additional data were collected for 12 patients with KRAS G12C -mutated NSCLC enrolled in a phase Ib cohort of the KRYSTAL-1 study and previously treated with sotorasib. The end points associated with both drugs included timing and severity of hepatotoxicity, best overall response, and duration of therapy. RESULTS All patients were treated with CPIs followed by sotorasib (initiated 0-64 days after CPI). All five real-world patients experienced hepatotoxicity with sotorasib that led to treatment discontinuation, whereas none experienced treatment-related hepatotoxicity with subsequent adagrasib treatment. Three patients from KRYSTAL-1 transitioned from sotorasib to adagrasib because of hepatotoxicity; one experienced grade 3 ALT elevation on adagrasib that resolved with therapy interruption and dose reduction. CONCLUSION Adagrasib may have a distinct hepatotoxicity profile from sotorasib and is more easily combined with CPIs either sequentially or concurrently. These differences may be used to inform clinical decisions regarding an initial KRAS G12C inhibitor for patients who recently discontinued a CPI or experience hepatotoxicity on sotorasib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcetonitrilesCarcinoma, Non-Small-Cell LungChemical and Drug Induced Liver InjuryLung NeoplasmsPiperazinesPyridinesPyrimidinesHumansProto-Oncogene Proteins p21(ras)Retrospective Studies

Substanzen

AcetonitrilesadagrasibKRAS protein, humanPiperazinesProto-Oncogene Proteins p21(ras)PyridinesPyrimidinessotorasib

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Boston, MA.
  • Brigham and Women's Hospital, Boston, MA.
  • Harvard Medical School, Boston, MA.
  • University of Michigan, Ann Arbor, MI.
  • Virginia Cancer Specialists, Fairfax, VA.
  • Mayo Clinic, Jacksonville, FL.

ORCID-Profile: Jia Luo, Narjust Florez, Yanyan Lou, Kevin Lu, Alexander I Spira, Hatim Husain

Zitieren

APA

Luo, J., Florez, N., Donnelly, A., Lou, Y., Lu, K., Ma, P. C., Spira, A. I., Ryan, D., & Husain, H. (2024). Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS G12C -Mutated Non–Small Cell Lung Cancer: A Case Series and Literature Review. JCO Precision Oncology. https://doi.org/10.1200/po.23.00644

Vancouver

Luo J, Florez N, Donnelly A, Lou Y, Lu K, Ma PC, et al. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS G12C -Mutated Non–Small Cell Lung Cancer: A Case Series and Literature Review. JCO Precision Oncology. 2024. doi:10.1200/po.23.00644

BibTeX
@article{Luo2024,
  author = {Luo, Jia and Florez, Narjust and Donnelly, Anjali and Lou, Yanyan and Lu, Kevin and Ma, Patrick C and Spira, Alexander I and Ryan, Debra and Husain, Hatim},
  title = {Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS G12C -Mutated Non–Small Cell Lung Cancer: A Case Series and Literature Review},
  journal = {JCO Precision Oncology},
  year = {2024},
  number = {8},
  doi = {10.1200/po.23.00644}
}
Kostenlos starten →